Hims is one of the many platforms that offer telehealth online from licensed providers, with services spanning from skincare and hair loss to anxiety and erectile dysfunction. In this review, we ...

Hims & Hers is revolutionizing healthcare with affordable, convenient telehealth services, leading to a 260% stock increase in the last year. The company benefits from GLP-1 drug sales and is ...

Hims & Hers (NYSE: HIMS) fell as much as 12% in trading on Wednesday after pharmaceutical company Novo Nordisk (NYSE: NVO) asked the FDA to not allow companies to compound GLP-1 semaglutide. This ...

Hims & Hers Health Inc. said an analysis of more than 10,000 patients taking a copycat version of Novo Nordisk A/S’s Ozempic and Wegovy showed the shot was a safe and effective way to shed pounds.

Hims & Hers Health will join the S&P SmallCap 600 prior to the opening of trading on Wednesday. Hims & Hers will replace Vector Group, which is being acquired by JT Group. Hims & Hers Health Inc ...

Hims & Hers Health, Inc. HIMS is scheduled to report third-quarter 2024 results on Nov. 4, after the closing bell. In the last reported quarter, the company’s earnings per share (EPS) of 6 cents ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Hims & Hers Health, Inc. HIMS shares rallied 10.1% in the last trading session to close at $19.44. This move can be attributable to notable volume with a higher number of shares being traded than ...

Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $18.73, moving -0.11% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 0.71%.

Allen Lutz, an analyst from Bank of America Securities, maintained the Buy rating on Hims & Hers Health (HIMS – Research Report). The associated price target remains the same with $25.00.